Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low-density lipoprotein-lowering medication and platelet function.

Patrizia Ferroni1, Stefania Basili, Francesca Santilli

  • 1Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele, Rome, Italy.

Pathophysiology of Haemostasis and Thrombosis
|August 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age-related efficacy of aspirin in secondary prevention of coronary artery disease: START-ANTIPLATELET registry and meta-analysis of randomized trials.

The American journal of medicine·2026
Same author

Significance of 8-iso-PGF<sub>2α</sub> in cardiovascular diseases.

American heart journal plus : cardiology research and practice·2026
Same author

GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies.

Diabetes research and clinical practice·2026
Same author

Circulating S100A8/A9 drives faster platelet COX-1 recovery via MRP4, impairing the duration of aspirin response.

Blood advances·2026
Same author

Reanimation of Stored Tissue Biopsies: A Functional Study and Translational Approach.

International journal of molecular sciences·2026
Same author

Circulating S100A8/A9 drives faster platelet COX-1 recovery via MRP4, impairing the duration of aspirin response.

Blood advances·2025

High low-density lipoprotein cholesterol (LDL-C) impacts atherosclerosis and platelet function. LDL-C-lowering drugs show varied effects on platelet activity, with statins and fibrates demonstrating anti-thrombotic potential.

Area of Science:

  • Cardiovascular Science
  • Pharmacology

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for atherosclerosis, cardiovascular morbidity, and mortality.
  • LDL-C influences platelet function through various mechanisms, potentially enhancing thrombotic events.

Purpose of the Study:

  • To review the impact of LDL-C on platelet function.
  • To evaluate the effects of different LDL-C-lowering agents on platelet activity and their implications for vascular protection.

Main Methods:

  • Literature review of studies investigating LDL-C, platelet function, and lipid-lowering therapies.
  • Analysis of mechanisms by which LDL-C and its reduction affect platelet aggregation and sensitivity.

Main Results:

Related Experiment Videos

  • Increased or modified LDL enhances platelet function and agonist sensitivity.
  • Statins exhibit anti-platelet activity, contributing to their anti-thrombotic effects.
  • Fibrates inhibit platelet function, while bile acid sequestrants do not appear to affect it.

    • Conclusions:

    • LDL-C-lowering agents have diverse effects on platelet function.
    • Statins and fibrates show potential in vascular protection through anti-platelet mechanisms.
    • Further research is needed to fully understand the therapeutic benefits of these agents in plaque stabilization and thrombosis.